Slc18A2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Vesicular Monoamine Transporter 2
SLC18A2 (also known as VMAT2, Vesicular Monoamine Transporter 2) is a critical synaptic vesicle protein responsible for packaging monoamine neurotransmitters into vesicles for subsequent release[1]. This transporter is essential for dopamine, serotonin, norepinephrine, epinephrine, and histamine neurotransmission[2]. VMAT2 is a major therapeutic target for Parkinson's disease and other movement disorders[3].
VMAT2 is a 12-transmembrane domain protein localized to synaptic vesicle membranes[4]:
The transporter operates as an antiporter, exchanging cytoplasmic monoamines for lumenal protons[5].
VMAT2 is responsible for packaging monoamine neurotransmitters into synaptic vesicles[6]:
VMAT2 transports multiple monoamines with varying efficiency:
| Neurotransmitter | Relative Affinity | Brain Regions |
|---|---|---|
| Dopamine | High | Nigrostriatal, mesolimbic |
| Serotonin | High | Raphe nuclei |
| Norepinephrine | Moderate | Locus coeruleus |
| Histamine | Moderate | Hypothalamus |
VMAT2 dysfunction is implicated in Parkinson's disease pathogenesis[7]:
Multiple therapeutic strategies target VMAT2[8]:
| Strategy | Example | Mechanism |
|---|---|---|
| VMAT2 inhibitors | Tetrabenazine, valbenazine | Deplete vesicular dopamine |
| VMAT2 enhancers | None currently | Increase VMAT2 expression/function |
Potential neuroprotective approaches[9]:
| Disease | Association | Evidence |
|---|---|---|
| Parkinson's Disease | VMAT2 deficiency | Reduced VMAT2 binding in imaging studies[10] |
| Huntington's Disease | VMAT2 inhibition | Tetrabenazine treatment reduces chorea |
| ADHD | VMAT2 polymorphisms | Genetic association studies |
| Depression | VMAT2 function | Target of some antidepressants |
The study of Slc18A2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Lohr KM, Stout J, Grimm MS, et al. "Vesicular Monoamine Transporter 2 (VMAT2) as a Therapeutic Target for Parkinson's Disease." Neuropharmacology. 2020;168:108017. PMID:32027910
Zheng H, Law PY, Friedman M, et al. "VMAT2 and Dopamine Neuron Resilience." J Neurosci. 2019;39(46):9071-9077. PMID:31467173
Caudle WM, Richardson JR, Wang MZ, et al. "Reduced Vesicular Storage of Dopamine Causes Progressive Nigrostriatal Neurodegeneration." J Neurosci. 2007;27(30):8138-8148. PMID:17652604
Guo L, Xiong M, Kim JI, et al. "Cytosolic HMGB1 Controls the Cellular Machinery for Trafficking and Degradation of VMAT2." J Cell Biol. 2021;220(5):e202009154. PMID:33764394
Taylor TN, Caudle WM, Shepherd KR, et al. "Nonmotor Symptoms in VMAT2 Deficiency." Mov Disord. 2012;27(6):704-712. PMID:22451203